In contrast, pimavanserin is a selective 5-HT2A inverse agonist, with negligible binding at almost all other receptors targeted by atypical APs, and thus is expected to treat psychosis symptoms in PD without worsening motor symptoms [19, 21]. The gene discussed is HTR2A; the disease is Parkinson disease.